Comparative Effects of Aspirin and NHP-544C
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02189122 |
Recruitment Status :
Completed
First Posted : July 14, 2014
Results First Posted : June 3, 2016
Last Update Posted : July 12, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Bradykinin Drug: Aspirin 81 mg Drug: Aspirin 162 mg Drug: NHP544-C 81 mg Drug: NHP544C 162 mg Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 61 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Basic Science |
Official Title: | Comparative Effects of Rapid-Release Aspirin and NHP-544C on Basal and Bradykinin Stimulated Prostacyclin Production |
Study Start Date : | July 2014 |
Actual Primary Completion Date : | July 2015 |
Actual Study Completion Date : | July 2015 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Group 1:Aspirin/placebo
Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
|
Drug: Bradykinin
Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Other Name: BK Drug: Aspirin 81 mg Subjects will take Aspirin 81 mg per day for five days.
Other Name: ASA 81 mg Drug: Aspirin 162 mg Subjects will take aspirin 162 mg per day for 5 days.
Other Name: ASA 162 mg Drug: Placebo Subjects will take matching placebo for five days. |
Active Comparator: Group 2:NHP-544C/placebo
Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
|
Drug: Bradykinin
Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Other Name: BK Drug: NHP544-C 81 mg Subjects will take NHP544C 81 mg per day for five days. Drug: NHP544C 162 mg Subjects will take NHP544C 162 mg once a day for five days. Drug: Placebo Subjects will take matching placebo for five days. |
- Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose [ Time Frame: 24 hour collection ]
- Urine Thromboxane Concentrations at 81mg ASA or NHP-544C Dose [ Time Frame: 24 hour collection ]
- Urine Thromboxane Concentrations at 162.5 mg ASA or NHP-544C Dose [ Time Frame: 24 hour collection ]
- Urine Prostacyclin Concentrations at Placebo ASA or Placebo NHP-544C Dose [ Time Frame: 24 hour collection ]
- Urine Prostacyclin Concentrations at 81 mg ASA or NHP-544C Dose [ Time Frame: 24 hour collection ]
- Urine Prostacyclin Concentrations at 162.5 mg ASA or NHP-544C Dose [ Time Frame: 24 hour collection ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Ages of 18 and 55 years, inclusive
- No significant medical issues without significant abnormal findings at the baseline physical examination
- Body mass index (BMI) between 18.0 and 30.0kg/m2 (weight (kg)/[height(m)]2)
- For women - negative pregnancy test on Period 1, Day -1, or surgically sterilized, or is at least two years post-menopausal prior to randomization. Females of childbearing potential must be practicing an acceptable method of birth control to be eligible. Acceptable forms of birth control include: condom plus spermicide or condom plus other form of birth control including hormonal method (IUD, patch, ring, implant, or injectable), sterilization of partner, or non-hormonal IUD. The use of oral contraceptives is allowed during the study, but the subject must be on a stable dose for 30 days prior to the trial and throughout all four dosing periods
- Ability to understand the requirements of the study and a willingness to comply with all study procedures
Exclusion Criteria:
- Clinically significant and relevant medical history (including failure of a major organ system) or current medical illness, and is deemed by the Principal Investigator to be unsuitable to participate in the study
- Participation in an investigational drug study within the 30 days prior to CRC admission
- Use of aspirin or other NSAID within 14 days of Day 1 of the study. All other medications, prescription (with the exception of contraceptives), over-the-counter (OTC), herbal, and vitamin supplements must be discontinued 7 days prior to Day 1. If subjects are taking prescription medication, or OTC medication at the direction of a health care provider, that provider must confirm that it is acceptable for them to stop dosing for the duration of the study
- History of metabolic, renal, hepatic, hemorrhagic stroke, gastrointestinal bleed, cardiovascular disease, central nervous system disorder, or peptic ulcer disease or other chronic bleeding disorder
- History of gastrointestinal disorder that could result in incomplete absorption of the study drug
- Malignancy, or neurologic or psychiatric disorder
- Abnormal laboratory value(s) determined to be clinically significant (in the opinion of the Investigator)
- History of illicit drug abuse in the past year or current evidence of such abuse in the opinion of the investigator
- Pregnancy or lactation
- Acute illness within 1 week of CRC admission
- Significant loss of blood or blood or plasma donation within 30 days of drug administration
- Hypersensitivity or allergy to NSAIDs, aspirin, ethylcellulose, polyvidone, castor oil, magnesium stearate, tartaric acid, colloidal anhydrous silica, talc, gelatin, titanium dioxide, erythrosine, or indigotin
- History of aspirin resistance
- History of alcohol abuse within past year. Current alcohol use should not exceed 14 standard alcoholic drinks per week. A drink is defined as 1.5 ounces (oz.) liquor, 12 oz. beer, or 6 oz. wine
- Alcohol consumption within 3 days of Day 1
- Difficulty swallowing oral medications
- Consumption of coffee or caffeine-containing beverages exceeding the equivalent of five 8-oz cups of coffee per day on average

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189122
United States, Tennessee | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States, 37232 |
Principal Investigator: | Nancy J Brown, MD | Vanderbilt University Medical Center |
Responsible Party: | Nancy J. Brown, M.D.; Professor of Medicine and Pharmacology, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT02189122 |
Other Study ID Numbers: |
140707 |
First Posted: | July 14, 2014 Key Record Dates |
Results First Posted: | June 3, 2016 |
Last Update Posted: | July 12, 2016 |
Last Verified: | June 2016 |
Aspirin Bradykinin Kininogens Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents |
Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Vasodilator Agents Cysteine Proteinase Inhibitors Protease Inhibitors |